A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects

NCT01652703 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

310

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia and High Risk for Cardiovascular Events

Interventions

BIOLOGICAL: Evolocumab
OTHER: Placebo

Sponsor

Amgen